Obiltoxaximab ELISA Kit

Catalog No.

KDX00401

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Bacillus anthracis PA has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Obiltoxaximab in the sample competitively binds to the pre-coated protein with biotin-labeled Obiltoxaximab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Obiltoxaximab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Obiltoxaximab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

12.5 - 800 ng/mL

Sensitivity

4.66 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	471.4	89.2	22.9	550.6	109.6	27.0
Standard deviation	49.4	9.3	4.4	109.6	12.0	3.6
CV (%)	10.5	10.5	19.3	19.9	11.0	13.4

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

ETI-204, CAS: 1351337-07-9

Background

Obiltoxaximab (ETI-204, trade name Anthim) is an affinity-enhanced, chimeric IgG1 kappa monoclonal antibody (mAb) developed by Elusys Therapeutics and the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) for the prevention and treatment of inhalational anthrax due to Bacillus anthracis. Obiltoxaximab binds the protective antigen (PA) component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa. Obiltoxaximab has been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. In March 2016, intravenous obiltoxaximab was approved in the USA for the treatment (in combination with appropriate antibacterial drugs) and prophylaxis of inhalational anthrax.

United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism., PMID:37594915

Pre- and Postlicensure Animal Efficacy Studies Comparing Anthrax Antitoxins., PMID:36251555

A Novel Toll-Like Receptor 2 Agonist Protects Mice in a Prophylactic Treatment Model Against Challenge With Bacillus anthracis., PMID:35369443

Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives., PMID:35099182

Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?, PMID:34712683

Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits., PMID:32876799

Monoclonal Antibodies Against Infectious Microbes: So Long and Too Little!, PMID:32164518

Obiltoxaximab (Anthim) for inhalation anthrax., PMID:30383733

New FDA approved antibacterial drugs: 2015-2017., PMID:32309599

Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen., PMID:29133571

Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans., PMID:29125719

New Drugs 2017, part 3., PMID:28991071

Obiltoxaximab: Adding to the Treatment Arsenal for Bacillus anthracis Infection., PMID:28573869

Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule., PMID:27925405

Alternative pre-approved and novel therapies for the treatment of anthrax., PMID:27809794

Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies., PMID:27568215

Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity., PMID:27431222

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax., PMID:27431219

Pharmaceutical Approval Update., PMID:27313431

Obiltoxaximab: First Global Approval., PMID:27085536

Antibodies to watch in 2016., PMID:26651519

Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax., PMID:25645849

Antibodies to watch in 2015., PMID:25484055

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge., PMID:15664918

Document Download

Obiltoxaximab ELISA Kit.pdf